The approval of Abrysvo by the European Commission is a positive development for Pfizer. This could potentially increase Pfizer's market share in the healthcare sector, as the drug is designed to protect a wide demographic - infants through maternal immunization and older adults from RSV. This could lead to increased sales and revenue for Pfizer, positively impacting its stock price in the short term.